| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | |||||||||||||||||||||||||
2 | COVID-19 A digest of peer-reviewed articles from top-ranked journals, preprints and press releases on selected research topics related to SARS-CoV-2 and COVID-19 | ||||||||||||||||||||||||
3 | |||||||||||||||||||||||||
4 | UPDATE OF 17 MARCH 2023 (most recently added papers are marked in blue) | ||||||||||||||||||||||||
5 | |||||||||||||||||||||||||
6 | Coordinated by: | Redaction Committee : | |||||||||||||||||||||||
7 | ANRS-EID/I3M: Erica Telford & Eric D'Ortenzio | ANRS-Emerging Infectious Diseases: Guia Carrara; Mario Delgado-Ortega; Erica Telford | |||||||||||||||||||||||
8 | Documented by (until Sept. 2020): Inserm- Collective Expertise Unit: Bénédicte Varignon & Laurent Fleury | With a precious contribution from: • Former members of the redaction committee: Claire Brugerolles; Eric D’Ortenzio; Evelyne Jouvin-Marche; Boris Lacarra; Claire Madelaine; Inmaculada Ortega-Perez; Xyomara Chavez-Pacheco; Oriane Puéchal; Renaud Vatrinet • Inserm- Department of Partnerships and External Relations (DPRE) • Inserm- USA office • The MODCOV19 Team | |||||||||||||||||||||||
9 | |||||||||||||||||||||||||
10 | |||||||||||||||||||||||||
11 | Journal | Date | Title (Hyperlink) | Authors and doi | Country | Field of expertise | |||||||||||||||||||
12 | JAMA Netw Open | 2023.03.16 | Analysis of Previous Infection, Vaccinations, and Anti–SARS-CoV-2 Antibody Titers and Protection Against Infection With the SARS-CoV-2 Omicron BA.5 Variant | Yamamoto S., et al. https://doi.org/10.1001/jamanetworkopen.2023.3370 | Japan | Immunology | |||||||||||||||||||
13 | JAMA Netw Open | 2023.03.16 | Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods | Link-Gelles R., et al. https://doi.org/10.1001/jamanetworkopen.2023.2599 | USA | Vaccines | |||||||||||||||||||
14 | Lancet Infect. Dis. | 2023.03.15 | Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system | Lewnard J.A., et al. https://doi.org/10.1016/S1473-3099(23)00118-4 | USA | Therapeutics | |||||||||||||||||||
15 | JAMA Netw Open | 2023.03.15 | Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods | Link-Gelles R., et al. https://doi.org/10.1001/jamanetworkopen.2023.2598 | USA | Vaccines | |||||||||||||||||||
16 | medRxiv | 2023.03.15 | Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection | Moyo-Gwete T., et al. https://doi.org/10.1101/2023.03.15.23287288 | South Africa | Vaccines | |||||||||||||||||||
17 | Nature Commun. | 2023.03.15 | Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain | Takano T., et al. https://doi.org/10.1038/s41467-023-37128-1 | Japan | Vaccines | |||||||||||||||||||
18 | Science Transl Med. | 2023.03.15 | Prior SARS-CoV-2 infection enhances and reshapes spike protein–specific memory induced by vaccination | Barateau V., et al. https://doi.org/10.1126/scitranslmed.ade0550 | France | Immunology | |||||||||||||||||||
19 | BMJ | 2023.03.15 | Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP | Hulme W.J., et al. https://doi.org/10.1136/bmj-2022-072808 | UK | Vaccines | |||||||||||||||||||
20 | Ann. Intern. Med. | 2023.03.14 | Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19 | Yuk Fai Wan E., et al. https://doi.org/10.7326/M22-3057 | Hong Kong/UK | Therapeutics | |||||||||||||||||||
21 | Nature Commun. | 2023.03.14 | Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome | Lewnard J.A., et al. https://doi.org/10.1038/s41467-023-37051-5 | USA | Variants | |||||||||||||||||||
22 | Nature Commun. | 2023.03.14 | Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein | Calvaresi V., et al. https://doi.org/10.1038/s41467-023-36745-0 | UK | Virology | |||||||||||||||||||
23 | PNAS | 2023.03.14 | Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age | Humbert M., et al. https://doi.org/10.1073/pnas.2220320120 | Sweden | Immunology | |||||||||||||||||||
24 | Lancet Infect. Dis. | 2023.03.13 | Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study | Tan C.Y., et al. https://doi.org/10.1016/S1473-3099(23)00060-9 | Singapore | Immunology | |||||||||||||||||||
25 | Clin Microbiol Infect. | 2023.03.13 | Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines; randomized trial, 3 months follow-up | Barda N., et al. https://doi.org/10.1016/j.cmi.2023.03.007 | Israel | Vaccines | |||||||||||||||||||
26 | NPJ Vaccines | 2023.03.11 | Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine | Benkeser D., et al. https://doi.org/10.1038/s41541-023-00630-0 | USA | Vaccines | |||||||||||||||||||
27 | Clin Infect Dis. | 2023.03.11 | Post-acute sequelae after SARS-CoV-2 infection by viral variant and vaccination status: a multicenter cross-sectional study | Kahlert C.R., et al. https://doi.org/10.1093/cid/ciad143 | Switzerland | Long Covid | |||||||||||||||||||
28 | Lancet Infect. Dis. | 2023.03.10 | Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study | Chemaitelly H., et al. https://doi.org/10.1016/S1473-3099(23)00058-0 | Singapore | Vaccines | |||||||||||||||||||
29 | Nature Commun. | 2023.03.10 | Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates | Pavot V., et al. https://doi.org/10.1038/s41467-023-36908-z | International / France | Vaccines | |||||||||||||||||||
30 | JAMA Network Open | 2023.03.09 | Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada | Summer M.W., et al. https://doi.org/10.1001/jamanetworkopen.2023.2328 | Canada | Clinics | |||||||||||||||||||
31 | medRxiv | 2023.03.09 | COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history | Townsley H., et al. https://doi.org/10.1101/2022.07.07.22277367 | UK | Clinics | |||||||||||||||||||
32 | Nature Commun. | 2023.03.09 | SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity | Jaycox J.R., et al. https://doi.org/10.1038/s41467-023-36686-8 | USA | Immunology | |||||||||||||||||||
33 | PNAS | 2023.03.09 | Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection | Hariharan V.N., et al. https://doi.org/10.1073/pnas.2219523120 | USA | Therapeutics | |||||||||||||||||||
34 | Lancet | 2023.03.07 | Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX – REVOLUTIOn trial | Maia I.S., et al. https://doi.org/10.1016/j.lana.2023.100466 | Brazil | Therapeutics | |||||||||||||||||||
35 | Lancet Oncol. | 2023.03.07 | SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry | Cortellini A., et al. https://doi.org/10.1016/S1470-2045(23)00056-6 | International Study | Vaccines | |||||||||||||||||||
36 | Nature Commun. | 2023.03.07 | Long-term gastrointestinal outcomes of COVID-19 | Xu E., et al. https://doi.org/10.1038/s41467-023-36223-7 | USA | Long Covid | |||||||||||||||||||
37 | Nature Commun. | 2023.03.07 | Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes | Grewal R., et al. https://doi.org/10.1038/s41467-023-36566-1 | Canada | Vaccines | |||||||||||||||||||
38 | BMJ | 2023.03.07 | Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records | Xie Y., et al. https://doi.org/10.1136/bmj-2022-072705 | USA | Therapeutics | |||||||||||||||||||
39 | PNAS | 2023.03.07 | Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19 | Moreira T.G., et al. https://doi.org/10.1073/pnas.2220272120 | USA | Therapeutics | |||||||||||||||||||
40 | medRxiv | 2023.03.06 | Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral dynamics : implications to define correlates of protection against infection | Lingas G., et al. https://doi.org/10.1101/2023.03.05.23286816 | France | Immunology | |||||||||||||||||||
41 | Nature Immunol. | 2023.03.06 | Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course | Muri J., et al. https://doi.org/10.1038/s41590-023-01445-w | International | Immunology | |||||||||||||||||||
42 | eBioMedicine | 2023.03.02 | Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination | Underwood A.P., et al. https://doi.org/10.1016/j.ebiom.2023.104475 | Denmark | Immunology | |||||||||||||||||||
43 | Valneva | 2022.03.02 | Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001 | https://valneva.com/press-release/valneva-provides-clinical-and-regulatory-updates-for-its-covid-19-vaccine-vla2001/ | Press release | Vaccines | |||||||||||||||||||
44 | Clin Infect Dis. | 2023.03.02 | Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 (COVID-19) Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout | Lea A.N., et al. https://doi.org/10.1093/cid/ciad084 | USA | Clinic | |||||||||||||||||||
45 | NEJM | 2023.03.01 | Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines | Dedong L., et al. https://doi.org/10.1056/NEJMc2216233 | China | Vaccines | |||||||||||||||||||
46 | Nature Commun. | 2023.02.28 | Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life | Zerbo O., et al. https://doi.org/10.1038/s41467-023-36547-4 | USA | Vaccines | |||||||||||||||||||
47 | PNAS | 2023.02.28 | Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2 | Muñoz-Basagoiti J., et al. https://doi.org/10.1073/pnas.2214561120 | International | Therapeutics | |||||||||||||||||||
48 | JAMA Netw Open. | 2023.02.28 | Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves | Doll M.K., et al. https://doi.org/jamanetworkopen.2023.1181 | USA | Public health | |||||||||||||||||||
49 | JAMA Netw Open. | 2023.02.28 | Portable Breath-Based Volatile Organic Compound Monitoring for the Detection of COVID-19 During the Circulation of the SARS-CoV-2 Delta Variant and the Transition to the SARS-CoV-2 Omicron Variant | Sharma R., et al. https://doi.org/10.1001/jamanetworkopen.2023.0982 | USA | Diagnostics | |||||||||||||||||||
50 | BMJ Medicine | 2023.02.28 | Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort | Tran V-T., et al. http://dx.doi.org/10.1136/bmjmed-2022-000229 | France | Long Covid | |||||||||||||||||||
51 | Immunity | 2023.02.27 | SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses | Koutsakos M., et al. https://doi.org/10.1016/j.immuni.2023.02.017 | Australia | Immunology | |||||||||||||||||||
52 | bioRxiv | 2023.02.27 | Cutaneous jet-injection of naked mRNA vaccine induces robust immune responses without systemic vaccine spillage | Abbasi S., et al. https://doi.org/10.1101/2023.02.27.530188 | Japan | Vaccines | |||||||||||||||||||
53 | medRxiv | 2023.02.26 | Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents | Lopez P., et al. https://doi.org/10.1101/2023.02.22.23286317 | International | Vaccines | |||||||||||||||||||
54 | Nature Commun. | 2023.02.25 | Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2 | Higashi-Kuwata N., et al. https://doi.org/10.1038/s41467-023-36729-0 | Japan | Therapeutics | |||||||||||||||||||
55 | medRxiv | 2023.02.24 | Safety of the NVX-CoV2373 COVID-19 Vaccine in Randomized Placebo-Controlled Clinical Trials | Smith K., et al. https://doi.org/10.1101/2023.02.24.23285601 | USA | Vaccines | |||||||||||||||||||
56 | Science Immunol. | 2023.02.23 | Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19 | Zhu B., et al. https://doi.org/10.1126/sciimmunol.adf0348 | USA | Therapeutics | |||||||||||||||||||
57 | Nature Commun. | 2023.02.22 | Epidemiological impacts of the NHS COVID-19 app in England and Wales throughout its first year | Kendall M., et al. https://doi.org/10.1038/s41467-023-36495-z | UK | Public Health / Epidemiology | |||||||||||||||||||
58 | Clin Infect DIs. | 2023.02.22 | The COVID-19 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus Ritonavir Versus Untreated Controls | Pandit J.A., et al. https://doi.org/10.1093/cid/ciad102 | USA | Therapeutics | |||||||||||||||||||
59 | JAMA | 2023.02.22 | Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19 | Naggie S., et al. https://doi.org/10.1001/jama.2023.1650 | USA | Therapeutics | |||||||||||||||||||
60 | Gilead | 2023.02.21 | Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients | https://www.gilead.com/news-and-press/press-room/press-releases/2023/2/veklury-remdesivir-reduced-risk-of-mortality-in-hospitalized-covid19-patients-across-all-variant-time-periods-in-a-real-world-study-of-more-than-5 | Press release | Therapeutics | |||||||||||||||||||
61 | Lancet Respir Med. | 2023.02.21 | Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials | Amstutz A., et al. https://doi.org/10.1016/S2213-2600(22)00528-8 | International (France) | Therapeutics | |||||||||||||||||||
62 | Ann Intern Med. | 2023.02.21 | Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection | Deo R., et al. https://doi.org/10.7326/M22-2381 | USA | Clinic | |||||||||||||||||||
63 | Nature Metab. | 2023.02.20 | Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity | Yoshiji S., et al. https://doi.org/10.1038/s42255-023-00742-w | International | Clinic | |||||||||||||||||||
64 | Lancet Regional Health Americas | 2023.02.19 | Safer at school early alert: an observational study of wastewater and surface monitoring to detect COVID-19 in elementary schools | Fielding-Miller R., et al. https://doi.org/10.1016/j.lana.2023.100449 | USA | Public health / Epidemiology | |||||||||||||||||||
65 | Lancet Child Adolesc Health | 2023.02.17 | Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial | Gao L., et al. https://doi.org/10.1016/S2352-4642(22)00376-5 | China | Vaccines | |||||||||||||||||||
66 | medRxiv | 2023.02.16 | Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project | Lange B., et al. https://doi.org/10.1101/2023.02.16.23285816 | Germany | Immunology | |||||||||||||||||||
67 | Lancet Microbe | 2023.02.15 | Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-sectional study | Ashworth J., et al. https://doi.org/10.1016/S2666-5247(22)00295-6 | International | Immunology | |||||||||||||||||||
68 | NEJM | 2023.02.16 | Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age | Muñoz F.M., et al. https://doi.org/10.1056/NEJMoa2211031 | International | Vaccines | |||||||||||||||||||
69 | NEJM | 2023.02.15 | Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis | Huth L., et al. https://doi.org/10.1056/NEJMc2216309 | Germany | Vaccines | |||||||||||||||||||
70 | Science Tranls Med. | 2023.02.15 | An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination | Carreño J.M., et al. https://doi.org/10.1126/scitranslmed.abo2847 | Thailand / USA | Vaccines | |||||||||||||||||||
71 | Science Tranls Med. | 2023.02.15 | Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose | Filardi B.A., et al. https://doi.org/10.1126/scitranslmed.ade6023 | Brazil / USA | Vaccines | |||||||||||||||||||
72 | Immunity | 2023.02.15 | Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease | Zhou P., et al. https://doi.org/10.1016/j.immuni.2023.02.005 | USA | Immunology | |||||||||||||||||||
73 | Lancet Global Health | 2023.02.15 | Genomic epidemiology of SARS-CoV-2 infections in The Gambia: an analysis of routinely collected surveillance data between March, 2020, and January, 2022 | Kanteh A., et al. https://doi.org/10.1016/S2214-109X(22)00553-8 | The Gambia | Public Health / Epidemiology | |||||||||||||||||||
74 | Nature Commun. | 2023.02.14 | Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies | Planas D., et al. https://doi.org/10.1038/s41467-023-36561-6 | France | Immunology | |||||||||||||||||||
75 | JAMA Netw Open | 2023.02.14 | Association of COVID-19 Vaccination With Risk for Incident Diabetes After COVID-19 Infection | Kwan A.C., et al. https://doi.org/10.1001/jamanetworkopen.2022.55965 | USA | Clinic | |||||||||||||||||||
76 | Nature Commun. | 2023.02.13 | Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria | Olawoye I.B., et al. https://doi.org/10.1038/s41467-023-36449-5 | Nigeria / USA | Variants | |||||||||||||||||||
77 | Lancet Infect Dis. | 2023.02.13 | Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study | Wong C.K.H., et al. https://doi.org/10.1016/S1473-3099(22)00873-8 | China | Therapeutics | |||||||||||||||||||
78 | Clin Infect Dis. | 2023.02.12 | Infection-induced immunity is associated with protection against SARS-CoV-2 infection and decreased infectivity | Frutos A.M., et al. https://doi.org/10.1093/cid/ciad074 | Nicaragua / USA | Immunology | |||||||||||||||||||
79 | MMRW | 2023.02.10 | COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022 | Johnson A.G., et al. http://dx.doi.org/10.15585/mmwr.mm7206a3 | USA | Vaccines | |||||||||||||||||||
80 | Lancet Infect Dis. | 2023.02.10 | Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study | Aggarwal N.R., et al. https://doi.org/10.1016/S1473-3099(23)00011-7 | USA | Therapeutics | |||||||||||||||||||
81 | Clin Infect Dis. | 2023.02.09 | One-year Outcomes of Lung Transplantation for COVID-19 Associated End Stage Lung Disease in the United States | Okumura K., et al. https://doi.org/10.1093/cid/ciad072 | USA | Clinic | |||||||||||||||||||
82 | Lancet Regional Health Southeast Asia | 2023.02.09 | Safety and efficacy of mycophenolate in COVID-19: a nonrandomised prospective study in western India | Sajgure A., et al. https://doi.org/10.1016/j.lansea.2023.100154 | India | Therapeutics | |||||||||||||||||||
83 | NEJM | 2023.02.09 | Early Treatment with Pegylated Interferon Lambda for Covid-19 | Reis G., et al. https://doi.org/10.1056/NEJMoa2209760 | International | Therapeutics | |||||||||||||||||||
84 | Nature Materials | 2023.02.09 | An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection | Mei X., et al. https://doi.org/10.1038/s41563-023-01475-7 | USA | Therapeutics | |||||||||||||||||||
85 | Lancet Public Health | 2023.02.09 | Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study | Imai N., et al. https://doi.org/10.1016/S2468-2667(22)00337-1 | UK | Public Health / Epidemiology | |||||||||||||||||||
86 | Lancet | 2023.02.08 | Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis | Pan Y., et al. https://doi.org/10.1016/S0140-6736(23)00129-0 | China | Virology | |||||||||||||||||||
87 | medRxiv | 2023.02.08 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study of oral RP7214, a DHODH inhibitor, in Patients with Symptomatic Mild SARS-CoV-2 Infection | Nair A., et al. https://doi.org/10.1101/2023.02.08.23285565 | India | Therapeutics | |||||||||||||||||||
88 | Nature Commun. | 2023.02.08 | Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2 | Venet M., et al. https://doi.org/10.1038/s41467-023-36140-9 | France | Immunology | |||||||||||||||||||
89 | Nature Commun. | 2023.02.08 | Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients | Rouet R., et al. https://doi.org/10.1038/s41467-023-36295-5 | Australia / Germany | Therapeutics | |||||||||||||||||||
90 | BMJ | 2023.02.08 | Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study | Jorgensen S.C.J., et al. https://doi.org/10.1136/bmj-2022-074035 | Canada | Vaccines | |||||||||||||||||||
91 | Clin Infect Dis. | 2023.02.08 | Relative effectiveness of COVID-19 vaccination and booster dose combinations among 18.9 million vaccinated adults during the early SARS-CoV-2 Omicron period — United States, January 1, 2022–March 31, 2022 | Kompaniyets L., et al. https://doi.org/10.1093/cid/ciad063 | USA | Vaccines | |||||||||||||||||||
92 | medRxiv | 2023.02.07 | Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France | Tamandjou C., et al. https://doi.org/10.1101/2023.01.11.23284137 | France | Public Health / Epidemiology | |||||||||||||||||||
93 | eClinicalMedicine | 2023.02.05 | Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022 | Nandi A., et al. https://doi.org/10.1016/j.eclinm.2023.101848 | USA/Italy | Public Health / Epidemiology | |||||||||||||||||||
94 | eClinicalMedicine | 2023.02.05 | Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study | Liu J., et al. https://doi.org/10.1016/j.lanwpc.2023.100694 | China | Therapeutics | |||||||||||||||||||
95 | Nature Commun. | 2023.02.04 | Direct Cryo-ET observation of platelet deformation induced by SARS-CoV-2 spike protein | Kuhn C.C., et al. https://doi.org/10.1038/s41467-023-36279-5 | International | Immunology | |||||||||||||||||||
96 | JAMA NetwOpen | 2023.02.03 | Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron | Wei Y., et al., https://doi.org/10.1001/jamanetworkopen.2022.54777 | Hong Kong | Vaccines | |||||||||||||||||||
97 | Clin Microbiol Infect. | 2023.02.03 | The association of neonatal SARS-CoV-2 anti-spike protein receptor-binding domain antibodies at delivery with infant COVID-19 infection under age 6 months: a prospective cohort study | Oz-Alkalay L, et al. https://doi.org/10.1016/j.cmi.2023.01.023 | Israel | Clinic | |||||||||||||||||||
98 | Nature Commun. | 2023.02.03 | Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity | Chen WH., et al. https://doi.org/10.1038/s41467-023-36106-x | USA | Therapeutics | |||||||||||||||||||
99 | JAMA Network Open | 2023.02.02 | Rates of and Factors Associated With Primary and Booster COVID-19 Vaccine Receipt by US Veterans, December 2020 to June 2022 | Bajema K.L., et al. https://doi.org/10.1001/jamanetworkopen.2022.54387 | USA | Vaccines | |||||||||||||||||||
100 | Nature Commun. | 2023.02.02 | High-depth sequencing characterization of viral dynamics across tissues in fatal COVID-19 reveals compartmentalized infection | Normandin E., et al. https://doi.org/10.1038/s41467-022-34256-y | USA | Virology | |||||||||||||||||||